{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:22Z","timestamp":1791868942131,"version":"4.3.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>\n                    ANCA vasculitis has an associated autoimmune response that produces ANCAs that induce distinct pathologic lesions. Pauci-immune necrotizing and crescentic GN is a frequent component of ANCA vasculitis. ANCA vasculitis is associated with ANCA specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). A diagnosis of ANCA vasculitis should always specify the serotype as MPO-ANCA positive, PR3-ANCA positive, or ANCA-negative. To fully characterize a patient, the serotype also should be accompanied by the clinicopathologic variant if this can be determined: microscopic polyangiitis, granulomatosis with polyangiitis (Wegener), eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss), or renal-limited vasculitis. ANCA vasculitis is most prevalent in individuals &gt;50 years old. There are racial\/ethnic and geographic influences on the prevalence, serotype frequencies, and clinicopathologic phenotypes. There is clinical,\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    , and animal model evidence that ANCAs cause disease by activating neutrophils to attack small vessels. Immunomodulatory and immunosuppressive therapies are used to induce remission, maintain remission, and treat relapses. Over recent years, there have been major advances in optimizing treatment by minimizing toxic therapy and utilizing more targeted therapy.\n                  <\/jats:p>","DOI":"10.2215\/cjn.02500317","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T20:11:37Z","timestamp":1503691897000},"page":"1680-1691","source":"Crossref","is-referenced-by-count":295,"title":["ANCA Glomerulonephritis and Vasculitis"],"prefix":"10.2215","volume":"12","author":[{"given":"J. Charles","family":"Jennette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1309\/WAEPADW0K4LPUHFN","article-title":"Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases","volume":"120","author":"Savige","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10157-013-0830-8","article-title":"Epidemiology and clinical features of systemic vasculitis","volume":"17","author":"Scott","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2215\/CJN.10871016","article-title":"Temporal and demographic trends in glomerular disease epidemiology in the southeastern United States, 1986-2015","volume":"12","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2010101058","article-title":"DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans","volume":"22","author":"Cao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.semarthrit.2013.11.011","article-title":"Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans","volume":"43","author":"Geetha","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for anti-neutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1440-1797.2011.01484.x","article-title":"Incidence and features of dual anti-GBM-positive and ANCA-positive patients","volume":"16","author":"DE Zoysa","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.ajkd.2005.01.001","article-title":"Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs","volume":"45","author":"Schlieben","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1172\/JCI65292","article-title":"Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis","volume":"123","author":"Roth","year":"2013","journal-title":"J Clin Invest"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000314776","article-title":"Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies","volume":"169","author":"Jennette","year":"2011","journal-title":"Contrib Nephrol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2016.00256","article-title":"Neutrophil extracellular traps in ANCA-associated vasculitis","volume":"7","author":"S\u00f6derberg","year":"2016","journal-title":"Front Immunol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cellimm.2013.04.007","article-title":"Myeloperoxidase (MPO)-specific CD4+ T cells contribute to MPO-anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis","volume":"282","author":"Gan","year":"2013","journal-title":"Cell Immunol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1189\/jlb.5A0116-037R","article-title":"Lessons from a double-transgenic neutrophil approach to induce antiproteinase 3 antibody-mediated vasculitis in mice","volume":"100","author":"Schreiber","year":"2016","journal-title":"J Leukoc Biol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ki.2015.202","article-title":"Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis","volume":"88","author":"O\u2019Sullivan","year":"2015","journal-title":"Kidney Int"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1681\/ASN.2016050548","article-title":"Gene-specific DNA methylation changes predict remission in patients with ANCA-associated vasculitis","volume":"28","author":"Jones","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm968","article-title":"Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3","volume":"10","author":"Pendergraft","year":"2004","journal-title":"Nat Med"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2008.309","article-title":"ANCA patients have T cells responsive to complementary PR-3 antigen","volume":"74","author":"Yang","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl 75","key":"B36-20230813","first-page":"S32","article-title":"Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis","volume":"31","author":"Poulton","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 1","key":"B42-20230813","doi-asserted-by":"crossref","first-page":"i171","DOI":"10.1093\/ndt\/gfv045","article-title":"Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2215\/CJN.03950412","article-title":"Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab","volume":"8","author":"Bunch","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B54-20230813","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: A randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis study group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201710000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:11Z","timestamp":1786369031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201710000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02500317","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]}}}